Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 290-294 (1 March 2007) | doi:10.1038/nm0307-290;
Challenges in tuberculosis drug research and development
&
Abstract
The present decade has seen a reawakening of tuberculosis (TB) drug research and development (R&D), spurred on by an urgent need to stem the tide of the disease globally and develop new, more effective treatments against drug-sensitive and resistant strains. As a result, there are now seven products in clinical development and the largest pipeline of early-stage projects and compounds in history.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
